Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers June 22, 2018
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - June 22, 2018

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

6/22/18 - Purchase Of Vaccines And Veterinary Drugs For Poultry [TendersInfo (India)]
Request for quotations: Purchase of vaccines and veterinary drugs for poultry. Live vaccine nobilis rismavac+ ca 126 against mareks disease 1+ 3 serotype with a solvent; 2 010 000 doses, 164 016 byn 2. Date and time of the end of acceptance of offers: 20.07. 2018 14:50 Major organization: OPEN JOINT-STOCK COMPANY 1 ST MINSK POULTRY PLANT Address: R
6/22/18 - Supply Of Veterinary Medicines 1.medicine/drugs Parenteral Injections (i) / Antibiotic Applications 2.medicine/drugs Parenteral Injections (i) / Antibiotic Applications [TendersInfo (India)]
Tenders are invited for Supply Of Veterinary Medicines 1. Medicine/Drugs Parenteral Injections/ Antibiotic Applications 2. Medicine/Drugs Parenteral Injections/ Antibiotic Applications Major organization: ANIMAL HUSBANDRY AND VETERINARY SERVICES Country: India Url: Tender notice number: 5-1/ DAHVS/Vety Med/2017/PF/1083...
6/21/18 - 2018 Competitor Analysis Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin
The "Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin" report has been added to' s offering. -New York esophageal squamous cell carcinoma-1: NY-ESO-1. The original reports were published in May and June 2018, respectively:.
6/21/18 - 2018 Competitor Analysis Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin -
The "Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin" report has been added to' s offering. Melanoma-associated antigen A: MAGE-A New York esophageal squamous cell carcinoma-1: NY-ESO-1 Human telomerase reverse transcriptase: hTERT Wilms tumor 1: WT1 Preferentially expressed antig
6/21/18 - AbbVie and Eisai Announce the Launch of HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL
TOKYO, June 21, 2018 AbbVie GK and Eisai Co., Ltd. announced that HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL, a new pediatric formulation of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody formulation, has been launched today after being listed in the National Health Insurance reimbursement price list on June 15. Outside of J
6/21/18 - Ablexis Targets Market Expansion Opportunities for AlivaMab Mouse Following Acquisition by Deerfield Management and the Founding of AlivaMab Discovery Services
BURLINGAME, Calif. and NEW YORK, June 21, 2018/ PRNewswire/ Ablexis LLC, and Deerfield Management announce today the acquisition of Ablexis by Deerfield Management. This acquisition creates a long-term partnership that will enable Ablexis to expand industry access to its AlivaMab Mouse technology, the company's innovative, next-generation transge
6/21/18 - ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other Events
ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Other EventsItem 8.01 Other Events. On June 15, 2018, Acceleron Pharma Inc. issued a press release titled "Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association." A copy of the press release is a
6/21/18 - Achieve Life Sciences, Inc. Announces Closing of a $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option [T-break Tech (Middle East)]
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the closing of an underwritten public offering of units for gross proceeds of $13.8 million, which includes the full exercise of the underwriter`s over-allotment option to.
6/21/18 - Active Pharmaceutical Ingredients Market 2018; Relish Tremendous Growth at a CAGR of 4.93% | Achieve Share worth USD 215 Billion by 2023 Avail at MRFR
"Active Pharmaceutical Ingredients Market" The report titled Global Active Pharmaceutical Ingredients Market 2018 Research Report implements an exhaustive study on Market Research Future. This Report Cover market size, growth rate, opportunities, market Dynamics and Factor Analysis. And also cover the other information such as Active Pharmaceutical
6/21/18 - AdoRx Therapeutics Announces Initial Funding of $10 Million for the Discovery of New Cancer Therapeutics
AdoRx Therapeutics, a UK based drug discovery company focused on the identification of new cancer therapeutics, today announced that it has closed an initial $10 million investment round financed by Epidarex Capital and CRT Pioneer Fund. AdoRx was founded in 2017 by leading healthcare investor Epidarex Capital and has assembled a group of highly.
6/21/18 - Aequus and Corium Join Forces to Advance Anti-Nausea Transdermal Patch
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today an expansion of its relationship with Corium International, Inc. to include the Company s long-acting transdermal patch, AQS1303, for the treatment of nausea and vomiting in pregnancy.
6/21/18 - Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel
DURHAM- Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of William Coppola as Intellectual Property Counsel, reporting to John
6/21/18 - Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug [Arab Finance (Egypt)]
Agios Pharmaceuticals, Inc. AGIO, announced the initiation of the phase III ACTIVATE study which will evaluateits lead rare genetic diseases candidate, AG-348 in patients with Pyruvate kinase deficiency who do not receive regular blood transfusions. The ACTIVATE study will enroll about 80 adult patients with PK deficiency who do not receive regular
6/21/18 - Agios Announces Initiation of Global Phase 3 Trial of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
CAMBRIDGE- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the initiation of the Phase 3 ACTIVATE trial evaluating AG-348, a first-in-class, selective, small molecule activator of the pyruvate kinase-R enzyme. ACTIVATE is a randomized, placebo-controlled trial that
6/21/18 - AIVITA Biomedical Announces U.S. Food and Drug Administration Clearance of IND for Phase II Glioblastoma Multiforme Trial [Syrian Arab News Agency]
AIVITA Biomedical, a biotech company specializing in innovative stem cell applications, announced today the U.S. Food and Drug Administration has cleared its Investigational New Drug application for a Phase II clinical trial investigating the Company`s ROOT OF CANCER technology in patients with glioblastoma multiforme. This will be the third...
6/21/18 - Albireo Appoints Jason G. Duncan as General Counsel and Secretary
BOSTON- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Jason G. Duncan as General Counsel and Secretary. In this role, Mr. Duncan will be responsible for Albireo's global legal affairs, and serve as a strategic advisor to the executive team and
6/21/18 - Alexion seeks approval from FDA for PNH drug ALXN1210 [Sudan Tribune]
Alexion Pharmaceuticals said that it has submitted a biologics license application to the US Food and Drug Administration, seeking approval for its C5 complement inhibitor ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Alexion executive vice president and research& development head John Orloff said: This first...
6/21/18 - Alimera Sciences Appoints Mary T. Szela to its Board of Directors
Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced Mary T. Szela has joined its Board of Directors. Ms. Szela brings extensive medical management and leadership experience to Alimera's Board. Prior to joining Surefire Medical as its CEO and President, Ms. Szela ser
6/21/18 - Alligator Bioscience's ATOR-1017 Strongly Activates Both T cells and NK Cells, Important for the Effective Eradication of Tumor Cells
Alligator Bioscience, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, will present additional preclinical data for the drug candidate ATOR-1017 at the 3rd Annual World Preclinical Congress in Boston, US. ATOR-1017 is a monoclonal antibody being developed for the treatment of metastasizing...
6/21/18 - Alnylam to Host Fifth Annual RNAi Roundtable Webcast Series
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it plans to host its 5 th annual series of RNAi Roundtable webcasts this summer. The 2018 series will offer a range of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in m
6/21/18 - Amgens blood cancer drug gets full EU licence [Tehran Times (Iran)]
Amgens Blincyto has been granted a full European licence in a form of blood cancer following data showing the drug almost doubled overall survival time compared with standard therapy. The company said the European Commission granted the marketing authorisation based on overall survival data from the phase 3 TOWER study, in adults with Philadelphia.
6/21/18 - Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients [Syrian Arab News Agency]
Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, today announced it received clearance from the Food and Drug Administration to initiate the first Phase 1 clinical trial of its immuno-oncology drug candidate AMXT 1501, a small molecule polyamine uptake inhibitor, and the approve
6/21/18 - Anti-Cancer Drugs Market Segment by Regions/Countries and Industry Analysis by Players Till 2021 Across the World: This Research Provides an in-depth analysis of Global Anti-Cancer Drugs Market By 2021. The Research profiles companies like F. Hoffman
Houston, TX 06/21/2018 Research N Reports has announced the addition of a new market intelligence report. Targeted pharmaceuticals for the global market have reached$ 89 billion in 2017. The global anticancer market is showing significant growth and is expected to grow at a significant CAGR over the period from 2018 to 2021. Some of the key p
6/21/18 - Appili Therapeutics to Present at 2018 Atlantic Venture Forum Technology Showcase
Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, announced today that it will present at the 2018 Atlantic Venture Forum Technology Showcase. The event takes place June 28-29, 2018 in Halifax, Canada. Presentation details are as follows: Date: Thursday, June 28, 2018 Time: 2 p.m. Atlantic time Sessio
6/21/18 - Arbutus Biopharma to Present at First Annual Roivant Pipeline Day
VANCOUVER- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that it will present at the first annual Roivant Pipeline Day on July 10, 2018, at 4:00 p.m. ET. Roivant Pipeline Day will be held on Tuesday, July 10, 2018, in New York City. Arbutus Biopharma Corporation is a publicly tra
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement